Modular CNV and SNV Testing for PML Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately predict who is at risk of developing progressive multifocal leukoencephalopathy (PML), a rare and potentially fatal opportunistic infection, despite known risk factors, necessitating a companion diagnostic to exclude high-risk individuals and ensure safe drug treatment.
Innovation Solution
A genetic test is developed to identify genetic variations associated with PML risk, using microarray analysis, PCR, or sequencing to analyze polynucleic acid samples for CNVs and SNVs, particularly in subjects with conditions like multiple sclerosis or Crohn's disease, to assess predisposition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If genetic testing is performed to identify PML risk, then prediction accuracy is improved, but device complexity and cost increase
Solution Approach 1:
The genetic test is divided into multiple independent components including microarray analysis for CNV detection, PCR for amplification, and sequencing for SNV detection. Each component can be performed separately and contributes to the overall risk assessment, making the complex testing process more manageable and modular.
Solution Approach 2:
The genetic testing system is designed to detect multiple types of genetic variations (CNVs and SNVs) using a unified platform that can analyze polynucleic acid samples for various genetic markers associated with PML risk, making the test applicable to different patient populations and clinical scenarios.
2Reliability
If comprehensive genetic analysis is performed to identify all PML risk factors, then diagnostic yield is improved, but loss of time and resources increases
Solution Approach 1:
The testing protocol begins with microarray analysis to detect copy number variations (CNVs) first, which can be performed on bulk polynucleic acid samples without requiring individual sequence analysis. This preliminary step quickly identifies high-risk genetic configurations before proceeding to more time-consuming sequencing only when necessary.
Solution Approach 2:
The test focuses on detecting specific high-impact genetic variations (CNVs and SNVs in key genes) rather than performing exhaustive genome-wide analysis. By targeting only the most clinically relevant genetic markers associated with PML risk, the test achieves high diagnostic yield while limiting the time and resource investment required.
Data Source
Figure 1
Figure 1
Figure 2
AI summary
This document provides methods and materials related to treating a disease. For example, this document provides methods for treating a subject's disease based on identifying the risk of progressive multifocal leukoencephalopathy PML using a genetic test.